Trials / Completed
CompletedNCT00293813
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 247 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- 50 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alendronate | Alendronate 70 mg PO QW |
| DRUG | Denosumab | denosumab 60 mg SC q 6 mos |
| DRUG | Placebo | Placebo for alendronate and placebo for denosumab |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2008-03-01
- Completion
- 2008-08-01
- First posted
- 2006-02-20
- Last updated
- 2014-07-25
- Results posted
- 2010-01-27
Source: ClinicalTrials.gov record NCT00293813. Inclusion in this directory is not an endorsement.